Health Costs

The MIDTERMS

KFF Health Tracking Poll: MAHA and the Midterms

Chemical food additive and pesticide concerns associated with the Make America Health Again (MAHA) movement are shared broadly across the public. But when it comes to voters, health care costs are a higher priority and bigger motivator, even among MAHA supporters, a new KFF Health Tracking Poll finds. When asked to identify their most important health priority for government to address, far more MAHA-supporting voters identify lowering the cost of health care (42%) than other issues more closely associated with the movement.

Affordable care act

ACA Marketplace Survey Feature Image - Website

Cost Concerns and Coverage Changes: A Follow-Up Survey of ACA Marketplace Enrollees

This KFF survey is a follow-up survey of adults who had ACA Marketplace insurance in 2025. The survey examines the cost concerns and coverage changes of Marketplace enrollees following the end of the enhanced premium tax credits and finds that half of returning enrollees say their health care costs are “a lot higher” and most expect to cut back on basic household expenses to afford coverage.

Health System Tracker

What Are the Recent Trends in Employer-Based Health Coverage? Employer-sponsored health insurance is the largest source of health coverage for people under 65, but its reach is uneven.

How Does U.S. Life Expectancy Compare to Other Countries? The life expectancy gap between the U.S. and peer countries decreased from 4.1 years in 2023 to 3.7 years in 2024 as U.S. mortality dropped.

How Does Cost Affect Access to Health Care? In 2024, about 1 in 6 adults reported delaying or not getting healthcare due to cost, including medical or mental health care.

How Does Health Spending in the U.S. Compare to Other Countries? While the U.S. still spends the most in total dollars, eight OECD nations had a higher percentage increase in per-person health spending in 2024.

Stay informed.

Stay informed.

Filter

1,191 - 1,200 of 1,582 Results

  • Early 2021 Data Show No Rebound in Health Care Utilization

    Issue Brief

    This analysis finds hospital admissions remained below expected levels in early 2021, suggesting much of the care people put off during the early months of the COVID-19 pandemic may have been forgone altogether.

  • Most private insurers are no longer waiving cost-sharing for COVID-19 treatment

    Issue Brief

    This analysis finds nearly three quarters of the largest health plans in each state are no longer waiving enrollees’ cost-sharing requirements for COVID-19 treatment as of August 2021. Insurers largely waived those costs early in the pandemic, before safe and effetive vaccines were available.

  • Unvaccinated COVID patients cost the U.S. health system billions of dollars

    Issue Brief

    This updated analysis for the Peterson-KFF Health System Tracker estimates that the preventable costs of treating unvaccinated patients in hospitals total $13.8 billion during the six-month period from June through November when the delta variant led to a surge in admissions.

  • Preventable Costs of Unvaccinated COVID-19 Patients Rise Sharply in August as Hospitalizations Surge

    News Release

    A surge in COVID-19 hospitalizations among people who have not been vaccinated in August is adding billions of dollars in preventable costs to the nation’s health-care system, an updated KFF analysis finds. In August, the new analysis estimates that the preventable costs of treating unvaccinated patients in  hospitals total $3.7 billion, almost twice the estimates for June and July combined. The total preventable costs for those three months now stand at an estimated $5.7 billion.…

  • Vaccines Are Free. Covid Care Is Not. Who Should Pay?

    Perspective

    In this commentary for Barron's, Cynthia Cox explores the impact to the American public as the U.S. health insurance system adjusts to the COVID-19 pandemic. She uses the experience of the past year and a half to raise questions about broader issues of fairness in the distribution of health care costs in the country.

  • Many Medicare Beneficiaries Face High Out-of-Pocket Costs for Dental and Hearing Care, Whether in Traditional Medicare or Medicare Advantage

    News Release

    Many Medicare beneficiaries face high annual out-of-pocket costs for dental and hearing care -- services that generally aren’t covered in traditional Medicare, but typically are covered by Medicare Advantage plans though the scope and value of these benefits vary, finds a new KFF analysis. The analysis shows that, among beneficiaries who used each type of service, average annual out-of-pocket spending was $914 for hearing care and $874 for dental care in 2018, but considerably less…

  • How Marketplace Costs and Premiums Will Change if American Rescue Plan Subsidies Expire

    News Release

    In a new Policy Watch, KFF analysts explore the potential impact of the expiration of the American Rescue Plan Act’s enhanced financial help and new eligibility for the Affordable Care Act’s health insurance Marketplace federal subsidies. While the COVID-19 relief legislation passed earlier this year provides greater subsidy assistance through 2022, Democrats in Congress are currently considering making the temporary federal help permanent or extending it as part of their planned budget reconciliation legislation. The…

  • What Do State Plans Reveal About Their Readiness to Distribute COVID-19 Vaccines? 

    News Release

    With hopes that a COVID-19 vaccine or vaccines will be proven safe and effective soon, state and local public health authorities will play a critical role in ensuring the efficient distribution and administration of the vaccine. To assess the readiness of these local governments to take on these responsibilities, KFF reviewed the preliminary vaccine distribution plans submitted to the U.S. Centers for Disease Control and Prevention last month by the states and the District of…

  • FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries

    Issue Brief

    The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S. This brief analyzes the cost implications for Medicare and beneficiaries associated with Biogen's new FDA-approved Alzheimer's drug, which will cost $56,000 per year.